High-yield corporate bonds occupy a space where income potential meets credit risk, an area many investors monitor closely amid economic uncertainty. Comparing CDX and HYG highlights two different approaches to the same asset class: one uses an active, hedged derivative structure, while the other follows straightforward index replication. They do not go head-to-head so much as illustrate distinct philosophies for gaining exposure. This comparison looks at how fund structure, sector allocation, costs, and positioning affect results for income-oriented investors.
The Simplify High Yield ETF (CDX), launched in February 2022, aims to deliver high current income from high-yield bonds while reducing credit risk. Instead of holding individual bonds outright, the fund obtains most of its high-yield exposure through total return swaps, which can also generate extra income from securities-lending fees. Its largest holding is the Simplify Government Money Market ETF (SBIL), used as collateral, along with several high-yield total return swap contracts and Treasury bills.
A key differentiator for CDX is its proprietary "Quality minus Junk" (Q-J) hedge overlay. This involves a long, equal-weighted basket of about 100 higher-quality U.S. stocks offset by shorts in a similar basket of lower-quality equities that are more vulnerable to rising refinancing costs. The overlay seeks to neutralize equity beta and sector exposures, offering some protection when credit spreads widen. CDX is actively managed, with a net expense ratio of 0.25% (0.50% gross) and an effective duration of roughly 3.6 years. Its smaller size and derivative focus make it less liquid and less transparent than traditional bond ETFs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The iShares iBoxx $ High Yield Corporate Bond ETF (HYG) is a passive vehicle that tracks the Markit iBoxx USD Liquid High Yield Index, a rules-based collection of U.S. dollar-denominated, liquid high-yield corporate bonds. With around 1,300 holdings and more than $16 billion in assets under management, it ranks among the largest and most actively traded high-yield ETFs.
HYG spreads credit exposure across many issuers and sectors, with financials typically the largest allocation, followed by consumer cyclicals, communications, energy, and healthcare. Because of its broad diversification, no single issuer dominates; top positions such as CCO Holdings, TransDigm, Venture Global LNG, and Tenet Healthcare each represent only a modest share. HYG carries a 0.49% expense ratio and an effective duration in the low- to mid-single digits, leaving it directly exposed to interest-rate shifts and credit-spread changes.
High-yield credit remains sensitive to several macro drivers. Elevated financing costs increase refinancing pressure on lower-rated borrowers, while solid corporate earnings and relatively contained default expectations have helped support spreads in recent cycles. Capital continues to flow into fixed-income ETFs as investors pursue yield, though rate uncertainty still influences performance. Regulatory and liquidity factors also play a role, including the expansion of private credit and changes in bank lending. For high-yield investors, the main risks center on credit-spread widening, rising defaults among weaker issuers, and interest-rate volatility that affects bond prices.
In recent months, HYG’s unhedged design has followed the broader high-yield market, benefiting from steady carry and firm credit conditions yet remaining exposed to spread-widening episodes. Its positioning is straightforward: broad sector exposure and strong liquidity make it a benchmark-style way to access high-yield beta.
CDX has followed a more distinct path. Its swap-based construction and Q-J hedge overlay aim to limit drawdowns during equity and credit stress, which can cause performance to diverge from the index in risk-off periods. In steadier, risk-on environments the hedge may moderate some upside. Volatility patterns reflect these choices: HYG tends to move with credit markets, while CDX targets a smoother, hedged profile. From what I see, the decision comes down to whether investors want raw high-yield beta or a hedged, cost-conscious alternative.
I often turn to Tickeron’s AI Screener when evaluating funds like these. The tool lets me quickly filter ETFs by technical patterns, fundamentals, and volatility metrics, helping refine comparisons without manual effort. It has become a regular part of how I review sector exposures and risk factors in my own work.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HYG saw its Momentum Indicator move below the 0 level on November 12, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned negative. In 51 of the 94 cases, the stock moved further down in the following days. The odds of a decline are at 54%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 64 cases where HYG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
HYG moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HYG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
HYG broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HYG's RSI Indicator exited the oversold zone, 11 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 50%.
The Moving Average Convergence Divergence (MACD) for HYG just turned positive on October 09, 2026. Looking at past instances where HYG's MACD turned positive, the stock continued to rise in 25 of 47 cases over the following month. The odds of a continued upward trend are 53%.
The 10-day moving average for HYG crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 39%.
Following a +0.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where HYG advanced for three days, in 149 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
The Aroon Indicator entered an Uptrend today. In 155 of 348 cases where HYG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 45%.